Vaccines and adjuvants – Special Issue

References

1. Baz Morelli A., Becher D., Koernig S., Silva A., Drane D., Maraskovsky E. 2012; ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol 61:935–943 [CrossRef]
   [Google Scholar]
2. Bijker E. M., Sauerwein R. W. 2012; Enhancement of naturally acquired immunity against malaria by drug use. J Med Microbiol 61:904–910[PubMed] [CrossRef]
   [Google Scholar]
3. Edwards J. E. Jr 2012; Fungal cell wall vaccines: an update. J Med Microbiol 61:895–903[PubMed] [CrossRef]
   [Google Scholar]
4. Kool M., Fierens K., Lambrecht B. N. 2012; Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol 61:927–934[PubMed] [CrossRef]
   [Google Scholar]
5. Oyston P. C., Robinson K. 2012; The current challenges for vaccine development. J Med Microbiol 61:889–894[PubMed] [CrossRef]
   [Google Scholar]
6. Terra V. S., Mills D. C., Yates L. E., Abouelhadid S., Cuccui J., Wren B. W. 2012; Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine design. J Med Microbiol 61:919–926[PubMed] [CrossRef]
   [Google Scholar]
7. Williamson D., Oyston P. C. F. 2012; The natural history and incidence of Yersinia pestis and prospects for vaccination. J Med Microbiol 61:911–918[PubMed] [CrossRef]
   [Google Scholar]